Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • ABTECT
  • Pipeline
    • Overview
    • Patients
    • Obefazimod for UC
    • Obefazimod for Crohn’s
    • Obefazimod for RA
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • General Meeting
  • Contact Us
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

Script

February 23, 2023

Abivax Banks €130m To Advance Obefazimod

Les Echos - Investir

February 22, 2023

La biotech Abivax lève 130 millions d’euros, soit 90% de sa capitalisation boursière au prix du marché

BioCentury

February 22, 2023

Quick Takes (subscribers only)

Healio Gastroenterology

September 12, 2022

Obefazimod bests placebo, improves ulcerative colitis in phase 2b induction trial

Les Echos investir

September 7, 2022

Abivax publie les résultats de l’étude de phase 2b d’obefazimod (ABX464) dans la rectocolite hémorragique

  • 1
  • 2
  • 3
  • 4
  • …
  • 46
© 2023 All rights reserved by ABIVAX | Website created by Stratégie et communication digitale : JLL CONSEIL Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Obefazimod for UC
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • General Meeting
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+